CytomX Therapeutics (CTMX) Treasury Shares (2014 - 2015)

CytomX Therapeutics (CTMX) has 8 years of Treasury Shares data on file, last reported at $2.7 million in Q1 2026.

• Quarterly Treasury Shares fell 4.78% year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (down 4.78% YoY) and the FY2025 annual result came in at $2.9 million, up 57.09% from the prior year.
• Treasury Shares retreated to $2.7 million in Q1 2026, from $2.9 million in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $2.9 million in Q4 2025 to a low of $397500.0 in Q3 2022.
• A 5-year average of $1.8 million and a median of $1.8 million in 2024 frame the typical range for Treasury Shares.
• Annual changes were most pronounced in 2023 — Treasury Shares soared 303.05% — and 2026, when it decreased 4.78%.
• Tracing CTMX's Treasury Shares over 5 years: stood at $1.2 million in 2022, then climbed by 15.47% to $1.4 million in 2023, then soared by 32.32% to $1.9 million in 2024, then jumped by 57.09% to $2.9 million in 2025, then dropped by 8.72% to $2.7 million in 2026.
• The last three Treasury Shares figures came in at $2.7 million (Q1 2026), $2.9 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.